The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)

Study acronym: RELIEF
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF).
Trial Details
NCT Number NCT07855692
Lead Sponsor Nagoya University
Conditions
(from sponsor)		 HFpEF - Heart Failure With Preserved Ejection Fraction
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov